- Home
- PHGE vs NLSP Comparison
PHGE vs NLSP Comparison
Compare PHGE & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- NLSP
- Stock Information
- Founded
- PHGE 2015
- NLSP 2015
- Country
- PHGE Israel
- NLSP Switzerland
- Employees
- PHGE N/A
- NLSP N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- PHGE Health Care
- NLSP Health Care
- Exchange
- PHGE Nasdaq
- NLSP Nasdaq
- Market Cap
- PHGE 12.6M
- NLSP 12.4M
- IPO Year
- PHGE N/A
- NLSP 2021
- Fundamental
- Price
- PHGE $0.55
- NLSP $1.83
- Analyst Decision
- PHGE Strong Buy
- NLSP
- Analyst Count
- PHGE 1
- NLSP 0
- Target Price
- PHGE $15.00
- NLSP N/A
- AVG Volume (30 Days)
- PHGE 292.1K
- NLSP 934.7K
- Earning Date
- PHGE 11-13-2025
- NLSP 10-06-2025
- Dividend Yield
- PHGE N/A
- NLSP N/A
- EPS Growth
- PHGE N/A
- NLSP N/A
- EPS
- PHGE N/A
- NLSP N/A
- Revenue
- PHGE N/A
- NLSP N/A
- Revenue This Year
- PHGE N/A
- NLSP N/A
- Revenue Next Year
- PHGE N/A
- NLSP N/A
- P/E Ratio
- PHGE N/A
- NLSP N/A
- Revenue Growth
- PHGE N/A
- NLSP N/A
- 52 Week Low
- PHGE $0.34
- NLSP $1.30
- 52 Week High
- PHGE $1.16
- NLSP $5.64
- Technical
- Relative Strength Index (RSI)
- PHGE 56.74
- NLSP 41.34
- Support Level
- PHGE $0.50
- NLSP $1.76
- Resistance Level
- PHGE $0.54
- NLSP $2.15
- Average True Range (ATR)
- PHGE 0.03
- NLSP 0.21
- MACD
- PHGE 0.00
- NLSP -0.02
- Stochastic Oscillator
- PHGE 71.42
- NLSP 7.86
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.